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OBJECTIVE—Carbohydrate-responsive element–binding protein
(ChREBP) is a key transcription factor that mediates the effects of
glucose on glycolytic and lipogenic genes in the liver. We have
previously reported that liver-speciﬁc inhibition of ChREBP pre-
vents hepatic steatosis in ob/ob mice by speciﬁcally decreasing
lipogenic rates in vivo. To better understand the regulation of
ChREBP activity in the liver, we investigated the implication of
O-linked b-N-acetylglucosamine (O-GlcNAc or O-GlcNAcylation),
an important glucose-dependent posttranslational modiﬁcation
playing multiple roles in transcription, protein stabilization, nuclear
localization, and signal transduction.
RESEARCH DESIGN AND METHODS—O-GlcNAcylation is
highly dynamic through the action of two enzymes: the O-GlcNAc
transferase (OGT), which transfers the monosaccharide to serine/
threonine residues on a target protein, and the O-GlcNAcase
(OGA), which hydrolyses the sugar. To modulate ChREBP
OG in
vitro and in vivo, the OGT and OGA enzymes were overexpressed
or inhibited via adenoviral approaches in mouse hepatocytes and
in the liver of C57BL/6J or obese db/db mice.
RESULTS—Our study shows that ChREBP interacts with OGT
and is subjected to O-GlcNAcylation in liver cells. O-GlcNAcylation
stabilizes the ChREBP protein and increases its transcriptional
activity toward its target glycolytic (L-PK) and lipogenic genes
(ACC, FAS,a n dSCD1) when combined with an active glucose
ﬂux in vivo. Indeed, OGT overexpression signiﬁcantly increased
ChREBP
OG in liver nuclear extracts from fed C57BL/6J mice, lead-
ing in turn to enhanced lipogenic gene expression and to excessive
hepatic triglyceride deposition. In the livers of hyperglycemic
obese db/db mice, ChREBP
OG levels were elevated compared
with controls. Interestingly, reducing ChREBP
OG levels via OGA
overexpression decreased lipogenic protein content (ACC, FAS),
prevented hepatic steatosis, and improved the lipidic proﬁle of
OGA-treated db/db mice.
CONCLUSIONS—Taken together, our results reveal that O-
GlcNAcylation represents an important novel regulation of ChREBP
activity in the liver under both physiological and pathophysiolog-
ical conditions. Diabetes 60:1399–1413, 2011
T
he liver is responsible for the conversion of
excess dietary carbohydrates into triglycerides
(TGs) through de novo lipogenesis. Appropriate
control of this pathway is crucial because excess
fatty acids lead to hepatic steatosis and to related metabolic
diseases such as insulin resistance and type 2 diabetes (1).
In recent years, studies reported that liver transcription
factor carbohydrate-responsive element–binding protein
(ChREBP) is required for the induction of the glycolytic
enzyme L-pyruvate kinase (L-PK) by glucose, and that
acting in synergy with sterol regulatory element–binding
protein (SREBP)-1c, ChREBP is necessary for the induc-
tion of lipogenic genes (acetyl-CoA carboxylase [ACC] and
fatty acid synthase [FAS]) in response to glucose and in-
sulin (2–4). Importantly, liver-speciﬁc inhibition of ChREBP,
by decreasing lipogenic rates, improves hepatic steatosis
and insulin resistance in obese ob/ob mice (5,6). Therefore,
ChREBP could be a potential therapeutic target, and an
accurate knowledge of the mechanisms regulating its ac-
tivity is crucial for the development of pharmacological ap-
proaches for the treatment of metabolic diseases.
Under low glucose concentrations, ChREBP, which is
phosphorylated on serine-196 (Ser-196) and threonine-666
(Thr-666) residues, is cytosolic and inactive (7). When
glucose concentrations rise, ChREBP undergoes a ﬁrst
dephosphorylation on Ser-196, allowing its nuclear trans-
location, and a second on Thr-666, leading to the activation
of its target genes through the binding on the carbohydrate
responsive element (ChoRE) (7). We demonstrated the rel-
evance of modulating Ser-196 phosphorylation for ChREBP
intracellular localization in response to glucose and/or
glucagon (8). However, the fact that mutations of Ser-196
and/or Thr-666 do not result in a constitutively active form
of ChREBP (9) suggests that additional glucose-dependent
posttranslational modiﬁcations may be involved in ChREBP
activation.
Key transcription factors are modiﬁed by O-linked
b-N-acetylglucosamine (O-GlcNAcylation or O-GlcNAc) in
the liver (10–15). The discovery that FoxO1 and cAMP-
responsive element–binding protein (CREB)–regulated tran-
scription coactivator 2 (CRTC2), both involved in the tran-
scriptional regulation of gluconeogenesis (16,17), are
O-GlcNAcylated provided a novel mechanism by which
hyperglycemia reinforces hepatic glucose production and
worsens glucose intolerance (11,12,18). O-GlcNAcylation
is highly dynamic through the action of two enzymes: the
O-GlcNAc transferase (OGT), which transfers the mono-
saccharide to serine/threonine residues on a target pro-
tein, and the O-GlcNAcase (OGA), which hydrolyses the
sugar (19) (Fig. 1A). O-GlcNAcylation can modulate protein
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ORIGINAL ARTICLEFIG. 1. ChREBP interacts with OGT and is O-GlcNAcylated in a dynamic manner in HEK293T cells and in mouse hepatocytes. A: Schematic diagram
of the UDP-GlcNAc pathway. O-GlcNAcylation is an important posttranslational modiﬁcation that has been proposed to be a nutrient sensor
because the donor sugar, UDP-GlcNAc, receives input from multiple metabolic pathways. Activity of OGT, the enzyme that transfers the mono-
saccharide to serine/threonine residues, depends upon UDP-GlcNAc concentrations. Of glucose that enters the cells, 2–5% is used for production of
the donor sugar nucleotide. The addition of GlcNH2 directly enters the hexosamine biosynthetic pathway. PUGNAc is an inhibitor of the OGA that
hydrolyses the sugar. B: HEK239T cells were cotransfected with OGT (1 mg) and ChREBP
wt plasmids (1 mg) and incubated for 24 h under high
glucose conditions (G25). Immunoprecipitation (IP) of ChREBP was analyzed by immunoblotting with an OGT antibody. b-Actin was used as
loading control. Representative Western blots (Wb) are shown. n = 3 independent experiments. C: ChREBP-overexpressing HEK293T cells were
incubated under low glucose medium plus 5 mM GlcNH2 or transfected with an OGT-expressing vector or both. Representative Western blots are
shown. n = 3 independent experiments. D: Overexpression of OGA (1 mg) in HEK293T cells cultured in 25 mM glucose leads to a decrease in global
and transfected ChREBP
OG. Representative Western blots are shown. n = 3 independent experiments. E: Immunoprecipitated ChREBP from
primary mouse hepatocytes incubated for 24 h in either low glucose (G5) or high glucose plus insulin (G25i) was immunoblotted with an OGT
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actions (20–22). O-GlcNAcylation acts as a nutrient sensor,
since the intracellular concentration of the donor sugar for
O-GlcNAcylation, uridine diphosphate GlcNAc, rapidly
responds to ﬂux through multiple metabolic pathways.
O-GlcNAcylation is the end product of the hexosamine
biosynthetic pathway (Fig. 1A), a metabolic pathway that
has emerged as a major determinant of metabolic disorders
associated with insulin resistance and/or type 2-diabetes
(10,23,24).
In the current study, we report that O-GlcNAcylation, by
stabilizing the ChREBP protein and stimulating its tran-
scriptional activity, increases ChREBP activity under hy-
perglycemic conditions in the liver. In addition, we show
that modulation of ChREBP O-GlcNAcylation (ChREBP
OG)
through the activities of OGT and/or OGA enzymes is an
important determinant of fatty acid synthesis in the mouse
liver.
RESEARCH DESIGN AND METHODS
Six- to 12-week-old male C57BL/6J and db/db mice were purchased from
Elevage Janvier. Procedures were carried out according to the French guide-
lines for the care of experimental animals. Mice were adapted to the environ-
ment for 1 week prior to study and maintained in a 12-h light/dark cycle with
water and regular diet (65% carbohydrate, 11% fat, and 24% protein). Green
ﬂuorescent protein (GFP) (Laboratoire de Thérapie Génique, Nantes, France),
OGT (11), and OGA (24) adenovirus were delivered by penis vein injection
(5 3 10
9 plaque-forming units [pfu]/mouse). Seven days after OGT injection,
mice were fasted for 24 h or refed on a regular diet for 18 h. For OGA studies,
mice were killed in the fed state 10 days after adenoviral injection. For gavage
experiments, 24-h fasted mice received glucosamine (GlcNH2, 2.5 g/kg) or
glucose (5 g/kg) orally and were killed 4, 8, or 12 h later. Mice were killed after
an intraperitoneal anesthesia (a ketamine/xylazine mix). Livers were ﬂash-
frozen and stored at –80°C.
Glucose and insulin tolerance tests. Glucose tolerance tests were per-
formed by glucose gavage (1 g D-glucose/kg body wt) after an overnight fast.
Insulin tolerance tests were performed by intraperitoneal injection of human
regular insulin (0.75 unit insulin/kg body wt, Actrapid Penﬁll; NovoNordisk)
5 h after food removal. Blood glucose was determined using one-touch Accu-
Check glucometer (Roche).
Primary cultures of hepatocytes. Hepatocytes were isolated and cultured as
described (2). Hepatocytes were incubated under low glucose concentrations
(G5) for 24 h and then infected with speciﬁc adenovirus (5 pfu/cell: GFP, OGT
(11), OGA (24), short hairpin RNA [shRNA] ChREBP [shChREBP; Genecust]
or shRNAOGT [shOGT, Genecust]) for 5 h. Cells were then cultured in the
presence of low (5 mmol/L [G5]) or high (25 mmol/L [G25]) glucose and insulin
concentrations (100 nM) (G25i) for 24 h. For protein stability experiments,
hepatocytes were incubated in G5 or in G25i for 24 h. Cells were then incubated
with G5, G25i, or 5 mmol/L GlcNH2 for 8 h. Simultaneously added were 8 µM
of MG132 (a proteasome inhibitor [N-carbobenzoxyl-Leu-Leu-leucinal, 8 mmol/L
stock solution in DMSO, Sigma]) or DMSO.
Transfections in HEK293T cells. Human embryonic kidney cells (HEK293T)
were grown in 25 mM D-glucose Dulbecco’s modiﬁed Eagle’s medium sup-
plemented with 10% fetal calf serum. OGT, OGA (11), wild-type ChREBP
(ChREBP
wt), and the dephosphorylated ChREBP isoform (ChREBP
DP,m u -
tated on Ser-196 and Thr-666 residues [4]) plasmids were previously described.
Using lipofectamine 2000 (Invitrogen), 1 mg of plasmid was transfected in
HEK293T cells according to the manufacturer. Cells were then incubated in
G25 or G25i and/or 5 mmol/L GlcNH2. For ubiquitynilation experiments,
HEK293T cells were cotransfected with 1 mg of ChREBP
wt and with an
ubiquitin hemagglutinin (HA)-tagged plasmid. Cells were incubated in G25 for
24 h. MG132 (20 mM) or DMSO were added for 7 h. ChREBP immunoprecip-
itates were immunoblotted with HA antibodies to detect ubiquitinylated forms
of ChREBP.
Luciferase reporter assays. HepG2 hepatoma cells were grown in 25 mM
D-glucose Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal
calf serum and were transfected using 250 ng of a L-PK luciferase reporter
construct containing three ChoRE sequences as previously described or an
empty PGL-3 luciferase construct for control (25). Cotransfections were per-
formed using 250 ng of ChREBP
wt and 250 ng of b-galactosidase plasmid for
normalization. At 24 h posttransfection, cells were incubated with glucose
or PUGNAc for 4 h, and luciferase assay was performed after cell lysis.
b-Galactosidase assays were performed for normalization of ChoRE-luciferase
activity.
Immunoprecipitation and wheat germ agglutinin puriﬁcation. For
O-GlcNAc protein immunoprecipitation, cells were lysed on ice with radio-
immunoprecipitation (RipA) buffer (10 mmol/L Tris/HCl, 150 mmol/L NaCl,
1% Triton X-100 [v/v], 0.5% sodium deoxycholate [w/v], 0.1% sodium dodecyl
sulfate [w/v], and protease inhibitors; pH 7.4). For ChREBP immunoprecipi-
tation, cells were lysed on ice with IPH buffer (20 mmol/L Tris/HCl, 150 mmol/L
NaCl, 0.5% NP-40 [v/v], and protease inhibitors; pH 8.0). Cellular extracts were
then centrifuged at 20,000g for 10 min at 4°C. Supernatants were incubated
with 3 mL of the mouse monoclonal anti–O-GlcNAc antibody (RL2, Afﬁnity
Bioreagents) or 3 mL of the rabbit polyclonal anti-ChREBP antibody and
placed at 4°C overnight. Bound proteins were recovered after addition of
30 mL of Sepharose-labeled protein G (Sigma) or A (Invitrogen) for 1 h at 4°C.
Beads were gently centrifuged for 1 min and washed with the following buffers
for O-GlcNAc protein immunoprecipitation: RipA buffer, RipA supplemented
with 500 mmol/L NaCl and TNE (10 mmol/L Tris/HCl, 150 mmol/L NaCl, and
1mM EDTA; pH 7.4) in equal volume, and ﬁnally with TNE alone or with IPH
buffer for other speciﬁc immunoprecipitation. For coimmunoprecipitation,
cells were lysed on ice in the smooth IPH buffer. Whole cell extracts were
centrifuged at 20,000g for 10 min at 4°C, and supernatants were collected.
Three microliters of the anti-ChREBP antibody were added to the super-
natants overnight at 4°C, followed by an incubation with Sepharose-labeled
protein A for 1 h at 4°C. Beads were gently centrifuged for 1 min and washed
four times for 5 min each with the smooth lysis buffer. Bound proteins were
analyzed by Western blot with a polyclonal anti-OGT antibody (1:5000, Sigma).
For wheat germ agglutinin ([WGA] a speciﬁc GlcNAc lectin) precipitation,
cells were lysed with RipA buffer supplemented or not with 0.5 M of GlcNAc
(Sigma) and extracts (1 mg of proteins) were incubated with 30 ml of WGA
agarose beads (Sigma) with or without 0.5M GlcNAc for 2 h at 4°C. After three
washes (with or without 0.5M GlcNAc), proteins were eluted from the beads
in 23 Laemmli buffer and separated by SDS-PAGE.
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP)
assays were performed as previously described (11). Proteins were cross-
linked to DNA by addition of 1% formaldehyde to the fresh liver following
incubation for 15 min at 37°C. Sonication was performed by 15 10-s pulses.
Immunoprecipitation was performed with a ChREBP antibody (NB400–135;
Novus Biologicals). Immune complexes were captured with 50 ml of 50%
Protein G agarose/salmon sperm DNA (Upstate). DNA fragments were quan-
tiﬁed by real-time PCR. L-PK promoter primers were as follows: forward, 59-
GTCCCACACTTTGGAAGCAT-39 and reverse, 59-CCCAACACTGATTCTACCC-39.
Gene expression analysis. Total cellular RNAs were extracted using the
RNeasy Kit (Promega) (2). Primers used for cyclophilin, ChREBP, L-PK, ACC,
FAS, SCD1, SREBP-1, and OGA were previously described (2,8,24). Primers
used for OGT were as follows: sense, 59-TCGCACAGCTCTGTCAAAAA-39and
antisense, 59-GCCCTGGGTCGCTTGGAAGA-39. The relative quantiﬁcation for
a given gene was corrected to the cyclophilin mRNA values.
Liver extracts and immunoblot analysis. Nuclear and cytoplasmic extracts
werepreparedusingtheNE-PERextractionreagentkit(PierceBiotechnology).
Liver proteins (80 mg) were subjected to SDS-PAGE analysis. ChREBP (Novus
Biologicals), SREBP-1c (Interchim), ACC antibody (Cell Signaling), and OGT
(DM17; Sigma) were detected with polyclonal antibodies. The FAS antibody
was a gift from I. Dugail (Centre de Recherche des Cordeliers, Paris, France),
and the CRTC2 antibody was used as described (11). b-Actin (Sigma-Aldrich),
GAPDH, and lamin A/C antibodies were used as loading controls. ChREBP
immunohistochemistry was performed as described (8).
Metabolic analysis. Glucose-6-phosphate (G6P) concentrations were deter-
mined as described (2). Liver TG was measured with a colorimetric diagnostic
kit (Triglycerides FS; Diasys). Plasma TG and nonesteriﬁed fatty acids were
determined using an automated Monarch device (Bichat, Paris). Serum insulin
concentrations were determined using a rat insulin ELISA assay kit (Crystal
Chem) with a mouse insulin standard.
Staining techniques. For detection of neutral lipids, mouse hepatocytes and
liver cryosections were ﬁxed and stained with the Oil Red O technique (26)
using 0.23% dye dissolved in 65% isopropyl alcohol for 10 min.
Statistical analyses. The results are expressed as means 6 SEM. Statistical
signiﬁcance was assessed using the ANOVA test (StatView). Differences were
considered statistically signiﬁcant at P , 0.05.
antibody in order to evaluate the interaction between the two endogenous proteins. b-Actin was used as a loading control. Representative Western
blots are shown. n = 3 independent experiments. (A high-quality color representation of this ﬁgure is available in the online issue.)
C. GUINEZ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1401FIG. 2. Elevated O-GlcNAc levels by GlcNH2 administration in vivo increases ChREBP protein content. Four groups of C57BL/6J mice were studied:
a 24-h fasted group, a fasted group refed a regular diet for 18 h, and the last groups of mice were force-fed with glucose (5 g/kg) or GlcNH2 (2.5 g/kg)
after the fasting period. Mice were killed at the indicated time and livers were analyzed. A: Western blot (Wb) analysis of O-GlcNAc and ChREBP
levels. b-Actin was used as a loading control. Lanes were run on the same gel but were noncontiguous. Representative Western blots are shown.
Quantiﬁcation of the ratio of total ChREBP compared with b-actin content is shown. Data are means 6 SEM. n =6 –10 per group. **P < 0.005
compared with the fasting state. B:C h R E B P
OG was evaluated by puriﬁcation of proteins with an O-GlcNAc–speciﬁc lectin, WGA. Speciﬁcity of the
binding was conﬁrmed by GlcNAc (0.5 M) competition. A representative Western blot is shown. b-Actin was used as a loading control. Quantiﬁcation
of the ratio of ChREBPOG compared with total ChREBP content is shown. Data are means 6 SEM. n =6 –10 per group. **P < 0.005 compared with the
fasting state. C:I m m u n o ﬂuorescence analysis of ChREBP in liver sections from 24-h fasted, refed, and force-fed mice with either glucose (5 g/kg) or
GlcNH2 (2.5 g/kg) after the fasting period. No signal was obtained when liver sections were incubated with the secondary antibody only (data not
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ChREBP interacts with OGT and is O-GlcNAcylated in
HEK293T cells and in hepatocytes. We ﬁrst examined
whether ChREBP interacted with OGT and could be
modiﬁed by O-GlcNAcylation (Fig. 1). The interaction be-
tween ChREBP and OGT was detected in HEK293T cells
after cotransfection with OGT (11) and ChREBP
wt (27) (Fig.
1B). To demonstrate that OGT interaction with ChREBP
leads to its O-GlcNAcylation, HEK293T cells were cotrans-
fected with OGT and ChREBP
wt (Fig. 1C). Global
O-GlcNAcylation levels were enhanced by the addition of
5 mmol/L GlcNH2, which enters the hexosamine bio-
synthetic pathway downstream of the limiting step (Fig.
1A). Immunoprecipitated ChREBP was immunoblotted
with an anti–O-GlcNAc antibody, or conversely, immuno-
precipitated O-GlcNAcylated proteins were immunoblotted
with an anti-ChREBP antibody (Fig. 1C). ChREBP was
highly O-GlcNAcylated under GlcNH2 plus OGT conditions
(Fig. 1C). ChREBP
OG is a dynamic process, since overex-
pression of OGA, the enzyme responsible for global degly-
cosylation of proteins, markedly decreased ChREBPOG in
HEK293T cells (Fig. 1D).
We tested whether an interaction between ChREBP and
OGT also occurred in mouse hepatocytes (Fig. 1E). Hepato-
cytes were cultured under low (G5) or high glucose plus
insulin (G25i) for 24 h. OGT was copuriﬁed in ChREBP
immunoprecipitates, thereby revealing a direct interaction
between the two proteins. Interestingly, the interaction
between ChREBP and OGT was stronger under low glu-
cose concentrations (Fig. 1E).
GlcNH2 administration in vivo increases ChREBP pro-
tein concentrations in the liver. To investigate the effect of
O-GlcNAcylation on ChREBP expression and/or activity, nu-
tritional studies were performed in vivo (Fig. 2). Mice were
fasted for 24 h and were then either refed for 18 h on a regular
diet, or force-fed with glucose (5 g/kg) or GlcNH2 (2.5 g/kg).
Under fasting conditions, blood glucose and G6P con-
centrations were low (Supplementary Fig. 1), and as a
consequence, ChREBP protein content and mRNA levels
remain low (Figs. 2A and 2E). Low global glycosylation
levels (Fig. 2A)a n dC h R E B P
OG revealed by WGA were
detected in parallel. Incubation of lysates with 0.5 M free
GlcNAc revealed the speciﬁcity of the binding (Fig. 2B).
Under fasting conditions, ChREBP was cytosolic (Fig. 2C),
and as a result, ChREBP target gene L-PK was not induced
(Fig. 2E).
Under refed and glucose gavage conditions (all times
examined), blood glucose and hepatic G6P concentra-
tions were signiﬁcantly increased above fasting values
(Supplementary Fig. 1). Global and ChREBP
OG levels were
increased compared with fasting conditions (Figs. 2A and
2B). Under glucose gavage conditions, ChREBP protein
content was gradually increased over 12 h (Fig. 2A)b e -
cause of a time-dependent increase in mRNA levels (Fig.
2E). It should be noted, however, that the induction of the
L-PK gene occurred 12 h after the beginning of the glucose
gavage—and this despite the presence of nuclear ChREBP
as early as 4 h (Fig. 2C and 2E).
As soon as 4 h of GlcNH2 gavage, ChREBP protein
content was signiﬁcantly increased compared with both
fasting and glucose gavage conditions (Fig. 2A). After 8 h,
equivalent protein content was reached and was main-
tained up to 12 h after the starting time point of the
gavages (glucose and GlcNH2)( F i g .2 A). ChREBP
OG fol-
lowed a similar pattern (Fig. 2B). In contrast to glucose,
the GlcNH2-mediated induction of ChREBP was not as-
sociated with increased mRNA content (Fig. 2E). Be-
cause blood glucose and G6P concentrations were not
increased above fasting values during the course of the
GlcNH2 gavage (Supplementary Fig. 1), ChREBP remained
cytosolic (Fig. 2C). Nuclear ChREBP
OG protein (measured at
the 8 h time point) was lower than in nuclear extracts from
refed and glucose force-fed mice. (Fig. 2D), and as a con-
sequence L-PK was not induced (Fig. 2E). Our results
suggest that ChREBP stabilization by O-GlcNAcylation does
not lead to an active protein in the absence of an active
glucose ﬂux.
The role of O-GlcNAcylation on ChREBP stability was
further addressed in hepatocytes (Supplementary Fig. 2).
Global O-GlcNAcylation levels were enhanced in 5 mmol/L
GlcNH2 or in G25i conditions. Incubation with MG132 led to
a marked increase in ubiquitinylated proteins (Supplementary
Fig. 2B). Under G5 conditions, MG132 raised ChREBP con-
tent to comparable levels to that in G25i conditions. Under
GlcNH2 conditions, ChREBP content was also increased to
comparable levels to that in G25i conditions, but indepen-
dently of MG132 addition. The MG132-mediated increase
in ChREBP content was the result of a stabilization of
the protein, since ChREBP mRNA levels remained low.
L-PK expression was only induced under G25i conditions
(Supplementary Fig. 2C).
To determine whether ChREBP was regulated by ubiq-
uitinylation, ChREBP
wt was cotransfected in HEK293T
cells with an ubiquitin-tagged HA vector (Ubi-HA) to allow
the detection of ubiquitinylated forms. Addition of MG132
induced the stabilization of ubiquitinylated proteins as well
as ubiquitinylated forms of ChREBP
wt, as revealed by the
anti-HA antibody (Supplementary Fig. 2D). Our results
show that ChREBP is ubiquitinylated after addition of
MG132 and suggest that the O-GlcNAcylation stabilizes
the ChREBP protein.
Hepatic OGT overexpression increases ChREBP tran-
scriptional activity in fed mice. To address the func-
tional consequences of raising ChREBP
OG in vivo, OGT
overexpression was achieved in the liver of C57BL/6J mice
(Fig. 3). OGT expression was increased by two- to three-
fold, leading to a rise in global O-GlcNAcylation levels (Fig.
3A). As a consequence, ChREBP protein content was in-
creased, regardless of the nutritional status (Fig. 3A).
ChREBP
OG was increased in the livers of refed versus
fasted mice and was further increased in the OGT mouse
liver (Fig. 3C). The OGT-mediated increase in ChREBP
content was linked to a posttranslational stabilization of
the protein because ChREBP mRNA levels were not mod-
iﬁed (Fig. 3B). Interestingly, ChREBP
OG content was only
increased in nuclear extracts from refed OGT mice but
not in the livers of fasted OGT mice (Fig. 3D). This dif-
ference was most likely due to the lack of increase in
hepatic G6P concentrations in the livers of fasted OGT
mice (Supplementary Table 1).
shown). D: Detection of nuclear ChREBP
OG by WGA binding in nuclear extracts from 24-h fasted, refed, and/or force-fed mice with either glucose
(5 g/kg) or GlcNH2 (2.5 g/kg) for 8 h. A representative Western blot is shown. n =6 –10 per group. Lanes were run on the same gel but were
noncontiguous. E: Quantitative RT-PCR analysis of ChREBP (blacks bars) and L-PK (white bars) in the livers of the four groups of mice. Data are
means 6 SEM. n =6 –10 per group. *P < 0.01, **P < 0.005 compared with fasted mice (within the same color). (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1403FIG. 3. OGT overexpression increases ChREBP protein content and activity in the liver of C57BL/6J mice. OGT (5 3 10
9 pfu/mouse) was over-
expressed in the liver of C57BL/6J mice through penis vein injection. An equivalent dose of GFP adenovirus was used as control. Mice were fasted
for 24 h or refed a regular diet following the fasting period (n =6 –10 mice per group). A: Liver extracts were immunoblotted with O-GlcNAc,
ChREBP, and OGT antibodies. GFP was used as loading control. Representative Western blots (Wb) are shown. B: Quantitative RT-PCR analysis of
OGT and ChREBP. Data are means 6 SEM. n =6p e rg r o u p .* P < 0.01, OGT vs. GFP mice; #P < 0.01, refed vs. fasted. C: ChREBP
OG were obtained
by WGA binding experiments. Speciﬁcity of the binding was conﬁrmed by GlcNAc (0.5 mmol/L) competition. b-Actin was used as a loading control.
Lanes were run on the same gel but were noncontiguous. D: ChREBP levels (cytosolic and nuclear) and nuclear ChREBP
OG were analyzed by
Western blot. Lamin A/C was used as a control. Representative Western blots are shown. Lanes were run on the same gel but were noncontiguous.
E: ChREBP at the ChoRE containing region of the L-PK promoter were measured by ChIP analysis. Immunoprecipitated L-PK promoter sequence
was analyzed by quantitative PCR. Data are means 6 SEM. n = 3 per group. *P < 0.01 compared with fasted GFP mice; #P < 0.01 compared with
refed GFP mice. F: Quantitative RT-PCR analysis of L-PK. Data are means 6 SEM. n = 6 per group. *P < 0.01 compared with fasted GFP mice; ##P <
0.005 compared with refed GFP mice. (A high-quality color representation of this ﬁgure is available in the online issue.)
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localization in response to glucose (8), O-GlcNAcylation of the
ChREBP
DP was measured in HEK293T cells (Supplementary
Fig. 3). No signiﬁcant difference in O-GlcNAcylation was ob-
served between ChREBP
DP and ChREBP
wt, suggesting that
phosphorylation and O-GlcNAc modiﬁcation(s) do not com-
petitively occur on these sites. In agreement with this ob-
servation, translocation of ChREBP to the nucleus in
response to refeeding was not affected under OGT con-
ditions (Fig. 3D).
We next determined the importance of O-GlcNAcylation
on ChREBP transcriptional activity. ChIP analysis revealed
a 60% increased in ChREBP recruitment to the L-PK pro-
moter in the liver of refed OGT mice (Fig. 3E). As a con-
sequence, L-PK expression was signiﬁcantly stimulated
(Fig. 3F). To conﬁrm the contribution of O-GlcNAcylation
to ChREBP activity, luciferase activity of a L-PK reporter
construct (25) was measured in HepG2 cells cotransfected
with ChREBP
wt (27) (Supplementary Fig. 4). A 12-fold in-
crease in L-PK luciferase activity was measured under G25
conditions compared with G5. Addition of PUGNAc (5 mM),
an inhibitor of the OGA, which hydrolyses the sugar (Fig. 1A),
led to a further induction (30%), revealing that ChREBPOG
plays part in its transcriptional activity (Supplementary
Fig. 4).
Development of hepatic steatosis in OGT-overexpressing
mice. We next determined the effects of OGT overexpression
on glucose and lipid metabolism. A three- to ﬁvefold in-
crease in ACC, FAS, and SCD1 gene expression was
measured in refed GFP mice—an increase that was sig-
niﬁcantly potentiated in the liver of refed OGT mice (Fig.
4A). TG concentrations (Supplementary Table 1) as well as
the number of lipid droplets stained with Oil Red O were
markedly increased in the livers of refed OGT mice (Fig.
4B). Interestingly, lipogenic gene expression was not in-
duced in the livers of fasted OGT mice and remained as
low as in GFP fasted mice (Fig. 4A). This lack of induction
was linked to the lack of concomitant increase in G6P
concentrations (Supplementary Table 1) and in nuclear
ChREBP
OG in fasted OGT mice (Fig. 3D). OGT mice also
exhibited increased fasting blood glucose (Supplementary
Table 1 and Fig. 4C) as well as a moderate but signiﬁcant
glucose and insulin intolerance compared with GFP mice
(Fig. 4C). These metabolic alterations were associated with
elevated hepatic glucose-6-phosphatase (G6Pase) mRNA
levels (Fig. 4D). This effect was likely due to increased
CRTC2 O-GlcNAcylation (Fig. 4E), as previously shown
(11). However, it should not be excluded that the effect
observed on G6Pase could be directly linked to ChREBP
OG,
since G6Pase gene expression is stimulated by glucose and
that two ChoRE were identiﬁed on its promoter (28).
Lastly, because lipogenic gene expression is under the
synergistic action of ChREBP and SREBP-1c (29), mRNA
levels, precursor, mature forms, and O-GlcNAcylation of
SREBP-1c were measured (Supplementary Fig. 5). No
signiﬁcant modiﬁcation of SREBP-1c was observed upon
OGT overexpression, suggesting a lack of SREBP-1c invol-
vement in the OGT-mediated induction of lipogenic genes.
Overexpression and silencing of OGT in primary
mouse hepatocytes. We next determined whether the
OGT-mediated induction of lipogenic gene expression was
strictly dependent on ChREBP (Fig. 5). As we observed in
vivo (Fig. 3A and C), a threefold increased in OGT ex-
pression raised global O-GlcNAcylation levels and in-
creased ChREBP total protein content in primary mouse
hepatocytes (Fig. 5A and B). Under G25i conditions, L-PK,
FAS, and SCD1 gene expression was further increased
in OGT-overexpressing hepatocytes compared with GFP
cells. Interestingly, the stimulatory effect of OGT was lost
when ChREBP was silenced through a shRNA strategy
(Fig. 5B and C). The effect was the result of ChREBP deﬁ-
ciency. Indeed, under OGT1shChREBP conditions, ChREBP
protein content was markedly decreased compared to OGT
overexpression and returned to levels nearly comparable to
GFP conditions (Fig. 5B). SREBP-1c expression remained
unchanged under the culture conditions tested (Fig. 5C).
To conﬁrm the importance of modulating OGT activity
for ChREBP protein content and/or activity, OGT expres-
sion was silenced through a shRNA approach in mouse
hepatocytes (Fig. 6). ChREBP
OG was signiﬁcantly reduced
compared with control conditions when OGT expression
was knocked-down under G25i conditions (Fig. 6A and B).
Total ChREBP protein content was also markedly reduced
(Fig. 6A), independently of a decrease in ChREBP mRNA
levels (Fig. 6C). This observation is in agreement with
a destabilization effect of deglycosylated ChREBP protein.
Importantly, under shOGT conditions, ChREBP-target gene
expression (L-PK, ACC, FAS, and SCD1) was signiﬁcantly
decreased (Fig. 6C).
Altogether, our in vivo and in vitro results (Figs. 3–6)
demonstrate that modulating OGT activity (overexpression/
inhibition) affects glycolytic and lipogenic gene expression
through ChREBPOG.
OGA overexpression improves hepatic steatosis and
the lipidic proﬁle of db/db mice. Having determined that
O-GlcNAcylation increases ChREBP activity under refed
conditions and leads to excessive hepatic TG deposition
(Figs. 3 and 4), we determined, as a complementary ex-
periment, whether deglycosylation of ChREBP could im-
prove hepatic steatosis and related metabolic alterations
in obese mice. To this purpose, we chose to overexpress
the OGA enzyme through an adenoviral approach (24) in
the livers of db/db mice, rather than silencing OGT (Fig. 6),
in order to address the relevance of the OGT/OGA balance
for ChREBP activity and function in the liver (Fig. 7). First,
we observed that ChREBP
OG was increased in the liver
of GFP-db/db mice (compared with GFP controls) and
was correlated to increased ACC and FAS protein content
(Fig. 7D), elevated TG concentrations (Fig. 7E), steatosis
(Fig. 7C), and hyperglycemia (Supplementary Table 2) in
these mice. Ten days after OGA delivery, a moderate
increase in OGA expression was detected, in agreement
with the observation that OGA overexpression peak is
achieved 3 days after adenoviral injection (Fig. 7A) (30).
Nevertheless, signiﬁcant physiological and metabolic mod-
iﬁcations were observed; OGA-db/db mice showed de-
creased fasting blood glucose and improved glucose
tolerance compared with GFP-db/db mice (Supplementary
Table 2 and Fig. 7B)—metabolic improvements that were
associated with a decrease in the O-GlcNAcylation of
CRTC2 (Fig. 7D), a key coactivator involved in the control
of hepatic glucose production (11). Interestingly, OGA over-
expression also signiﬁcantly reduced ChREBPOG levels (Fig.
7D), a decrease that was associated with diminished ACC
and FAS protein content (Fig. 7D) and improved hepatic
steatosis (Fig. 7C). Histological analysis of liver sections
from OGA-db/db mice revealed a marked decrease in lipid
droplets size and number, as revealed by Oil Red O staining
(Fig. 7C). Supporting these observations, liver and plasma
TG levels were signiﬁcantly decreased (Fig. 7E). ChREBP
total protein content was also decreased in the liver of OGA-
db/db mice (Fig. 7D), likely as a result of a destabilization of
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OG-mediated induction of the lipogenic program in the liver of OGT mice. A: Quantitative RT-PCR analysis of ACC, FAS,a n dSCD1.
Data are means 6 SEM. n = 6 per group. *P < 0.01; **P < 0.005 compared with fasted GFP mice; #P < 0.005 compared with refed GFP mice. B:O i lR e d
O staining of liver sections from GFP and OGT mice (original magniﬁcation 320). C: Glucose tolerance (1 g/kg) and insulin tolerance (0.75 units/kg)
tests were performed in GFP and OGT mice. Data are means 6 SEM. n =6 –10 mice per group. *P < 0.01; **P < 0.005 compared with GFP mice.
D: Quantitative RT-PCR analysis of G6Pase. Data are means 6 SE. n = 6 per group. ##P < 0.005 compared with refed GFP mice. E:C R T C 2
OG were
obtained by WGA binding. Speciﬁcity of the binding was conﬁrmed by GlcNAc (0.5 mmol/L) competition. Representative Western blots (Wb) of
O-GlcNAcylated and total CRTC2 forms are shown. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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ciﬁc, since total CRTC2 protein content was not affected by
OGA treatment (Fig. 7D).
Taken together, our results reveal that increased
ChREBP
OG is correlated to hyperglycemia and steatosis in
db/db mice and that hepatic OGA overexpression, by af-
fecting ChREBP activity (O-GlcNAcylation and content),
signiﬁcantly improved the lipidic proﬁle and decreased
hepatic steatosis of db/db mice.
Deglycosylation of ChREBP reduces lipid droplet ac-
cumulation in hepatocytes. To conﬁrm the direct con-
sequence of modulating ChREBP
OG via OGA on lipid
synthesis, OGA was overexpressed in hepatocytes (Fig.
8A). OGA overexpression led to signiﬁcant reduction in
FIG. 5. The stimulatory effect of OGT on lipogenic gene expression is lost when ChREBP is silenced. Mouse hepatocytes were incubated under low
glucose concentrations (G5) and adeno-infected with 5 plaque-forming units/cell of GFP, OGT, shChREBP, or OGT+shChREBP adenovirus for 5 h. Cells
were then incubated for 24 h under low glucose (G5) or high glucose concentrations plus insulin (G25i). A: Quantitative RT-PCR analysis of OGT. Data
are means 6 SEM. n = 6 independent cultures. *P < 0.05 compared with GFP. B:G l o b a lO-GlcNAcylation levels and ChREBP protein content. b-Actin
was used as a loading control. Representative Western blots (Wb) are shown. n = 6 independent experiments. Lanes were run on the same gel but were
noncontiguous. C: Quantitative RT-PCR analysis of L-PK, FAS, SCD1,a n dSREBP-1c.* P < 0.05 compared with GFP (G25i); #P < 0.05 compared with
OGT (G25i). Data are means 6 SEM. n = 6 independent cultures.
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OG (Fig. 8B). ChREBP mRNA
concentrations were not affected, conﬁrming that OGA
only affects ChREBP at the posttranslational level (Fig.
8C). Surprisingly, in contrast to long-term OGA treatment
in vivo (10 days, Fig. 7), short-term OGA overexpression in
vitro (48 h) did not affect ChREBP total protein content
(Fig. 8B). As a direct consequence of decreased ChREBP
OG,
L-PK, ACC,a n dSCD1 expression was signiﬁcantly reduced
(Fig. 8C), leading to a visible decrease in lipid droplet ac-
cumulation after Oil Red O staining under G25i conditions
(Fig. 8D). Altogether, our results show that decreasing
ChREBP
OG affects its activity and prevents lipid accumu-
lation in primary hepatocytes.
DISCUSSION
Over the recent years, ChREBP has emerged as a cen-
tral regulator of lipid synthesis in the liver through the
transcriptional control of glycolytic and lipogenic gene
expression in response to glucose (2,8,31). The fact that liver-
speciﬁc inhibition of ChREBP improves hepatic steatosis
in obese ob/ob mice (5) prompted us to provide a better
knowledge of the regulation of its activity in the liver. So
far, phosphorylation had been the only posttranslational
modiﬁcation described to modulate ChREBP activity (7,9).
Interestingly, recent work from our laboratory revealed
that ChREBP is regulated by acetylation on speciﬁc lysines
in response to glucose (31). In the current study, we report
that ChREBP is also subjected to O-GlcNAcylation; O-
GlcNAcylation not only stabilizes the protein but also
increases its transcriptional activity toward its target genes
(L-PK, ACC, FAS, and SCD1) when combined with an
active glucose ﬂux in vivo. More importantly, our results
suggest that O-GlcNAcylation increases ChREBP activity
under hyperglycemic conditions and therefore leads to ex-
cessive TG deposition in the liver.
Several transcription factors are modiﬁed by O-
GlcNAcylation (10,15). This posttranslational modiﬁcation
FIG. 6. OGT silencing decreases ChREBP
OG levels and ChREBP-target gene expression in primary mouse hepatocytes. Mouse hepatocytes were
incubated under low glucose concentrations (G5) and adeno-infected with 5 pfu/cell of control (shCTRL) or shOGT adenovirus for 5h. Cells were
then incubated for 24 h under low glucose (G5) or high glucose concentrations plus insulin (G25i). A: ChREBP
OG were obtained by WGA binding.
Representative Western blots (Wb) of O-GlcNAcylated and total ChREBP protein are shown. n = 5 independent cultures. B: Quantiﬁcation of the
ratio of ChREBP
OG compared with total ChREBP content is shown. Data are means 6 SEM. n = 5 independent cultures. *P < 0.05 compared with G5
conditions; ##P < 0.01 compared with shCTRL conditions (G25i). C: Quantitative RT-PCR analysis of ChREBP, SREBP-1c, OGT, L-PK, ACC, FAS,
and SCD1. *P < 0.01; **P < 0.005; ***P < 0.001 compared with shCTRL (G25i). Data are means 6 SEM. n = 5 independent cultures. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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9 pfu/mouse) was overexpressed in the liver of db/db mice
through penis vein injection. An equivalent dose of GFP adenovirus was injected to C57BL/6J and toanother group of db/db mice. Mice were studied at
the fed state. n =5 –6m i c ep e rg r o u p .A: Quantitative RT-PCR analysis of OGA. *P < 0.05 compared with GFP mice. B: Glucose tolerance (1 g/kg) tests
were performed in GFP- and OGA-treated mice. Data are means 6 SEM. n =5 –6m i c ep e rg r o u p .* P < 0.01; **P < 0.005 compared with GFP-db/db mice.
C: Hepatic steatosis is prevented in OGA-db/db mice. Oil Red O staining of liver sections from GFP-C7BL/6J, GFP-db/db, and OGA-db/db mice (original
magniﬁcation 320). D: ChREBP
OG and CRTC2
OG levels, and ChREBP, ACC, FAS, and CRTC2 total protein content. GAPDH was used as a loading
control. Representative Western blots (Wb) are shown. Lanes were run on the same gel but were noncontiguous. E: Liver and plasma TG concen-
trations. *P < 0.01 compared with GFP-C57BL/6J mice; #P < 0.01 compared with GFP-db/db mice. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MAY 2011 1409FIG. 8. OGA overexpression in vitro leads to ChREBP deglycosylation and decreased lipid droplet accumulation. Primary mouse hepatocytes were
incubated under low glucose concentrations (G5) and adeno-infected with either 5 pfu/cell of GFP or OGA adenovirus for 5 h. Cells were then
incubated 24 h with high glucose concentrations plus insulin (G25i). A: Quantitative RT-PCR analysis of OGA. Data are means 6 SEM. n = 4 in-
dependent cultures. *P < 0.005 compared with GFP. B: Global and speciﬁc ChREBP
OG. b-Actin was used as a loading control. Representative
Western blots (Wb) are shown. n = 4 independent experiments. C: Quantitative RT-PCR analysis of ChREBP, L-PK, ACC,a n dSCD1.* P < 0.05;
**P < 0.01; ***P < 0.005 compared with GFP. Data are means 6 SEM. n = 4 independent cultures. D: Oil Red O staining of hepatocytes infected
with either 5 pfu/cell of GFP or OGA adenovirus (original magniﬁcation 340). (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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donor sugar, UDP-GlcNAc, receives input from multiple
metabolic pathways and the activity of OGT, the enzyme
that transfers the monosaccharide to serine/threonine res-
idues, depends upon UDP-GlcNAc concentrations (20) (Fig.
1A). O-GlcNAcylation regulates transactivation by altering
recruitment of transcriptional machinery, DNA binding,
nuclear localization, and/or protein stability (20,32). Sus-
tained increase in O-GlcNAc levels has been implicated as
a pathogenic contributor to glucose toxicity and insulin
resistance, major hallmarks of type 2 diabetes and diabetes-
related cardiovascular complications (33). Our study dem-
onstrates a direct interaction between ChREBP and OGT in
HEK293T cells and in hepatocytes. The fact that the in-
teraction was stronger under low glucose concentrations
suggests that ChREBP
OG may explain the residual ChREBP
content under low glucose availability. This mechanism
could lead to high ChREBP protein levels ready to be ac-
tivated when glucose ﬂux rapidly increases upon refeeding.
Our results reveal that O-GlcNAcylation affects ChREBP
protein stability, increasing ChREBP protein content in-
dependently of a stimulation of its transcription. Although
previously reported as a rather labile protein, with an esti-
mated half-life of 30 min (34), no study previously reported,
to our knowledge, the mechanism(s) by which the ChREBP
protein undergoes degradation in the liver. Our study
reveals that ChREBP is ubiquitinylated and probably
undergoes degradation through the proteasome, since
MG132 treatment resulted in ChREBP protein stabiliza-
tion under low glucose concentrations. Similar protein
content was reached when hepatocytes were incubated
with 5 mM GlcNH2, indicating that ChREBP was stabi-
lized by O-GlcNAcylation and protected against protea-
somal degradation (Supplementary Fig. 6). This is also in
agreement with the fact that proteasome function is
inhibited by O-GlcNAc (35). Interestingly, when OGA was
overexpressed in the liver of db/db mice, ChREBP total
protein content was decreased, most likely through a speciﬁc
destabilization of the deglycosylated ChREBP protein. In
addition, the decrease in blood glucose concentrations ob-
served upon OGA treatment in db/db mice (Supplementary
Table 2) may have also contributed to reduce ChREBP
content and/or O-GlcNAcylation. The fact that OGT silencing
in vitro also affected total ChREBP protein concentrations
(Fig. 6), supports the hypothesis that O-GlcNAcylation mod-
ulates ChREBP protein stability.
O-GlcNAcylation can also regulate the cellular localiza-
tion of transcription factors (22). Nuclear translocation is
a central determinant of ChREBP activity in response to
glucose. It was demonstrated that ChREBP is translocated
into the nucleus in response to high glucose concentra-
tions (34). It was thus hypothesized that glucose ﬂux
through the pentose phosphate pathway promoted the
formation of xylulose-5-phosphate, which then activated
the protein phosphatase 2A, which dephosphorylates Ser-196,
a cAMP-dependent protein kinase target residue, located near
the nuclear localization signal domain and promotes ChREBP
nuclear translocation (7). Although alternate mechanisms
were proposed to explain the glucose-mediated activation
of ChREBP (36), we reported that modulation of Ser-196
phosphorylation was a key determinant of ChREBP cellular
localization (8). Under fed conditions, ChREBP is nuclear
and dephosphorylated on Ser-196, whereas after a bolus of
glucagon, which actives cAMP-dependent protein kinase
activity and mimics a fasting state, ChREBP phosphoryla-
tion on Ser-196 is increased and the transcription factor is
exported from the nucleus to the cytoplasm. The current
study reports that ChREBP
OG does not affect its cellular
localization. Under fasting conditions, GlcNH2 treatment, or
OGT overexpression, ChREBP protein content is increased
but ChREBP nuclear localization is not modiﬁed, suggest-
ing that a signal dependent on glucose metabolism is still
needed for its translocation. When OGT is expressed in the
liver of fasted mice, only a low fraction of ChREBP
OG is
detected in liver nuclear extracts, suggesting that under
low glucose availability O-GlcNAcylation stabilizes the
ChREBP protein but does not allow its nuclear trans-
location. The fact that O-GlcNAcylation of the ChREBP
DP
was not reduced compared with the one of ChREBP
wt
suggests that O-GlcNAcylation and phosphorylation do
not competitively occupy these particular sites, and that
Ser-196, which is important for ChREBP nuclear trans-
location, is still accessible to dephosphorylation when
ChREBP is O-GlcNAcylated. The identiﬁcation of the spe-
ciﬁc O-GlcNAcylation residues within the ChREBP protein
will be important in the future to determine their speciﬁc
contribution to ChREBP transcriptional activity and/or
modulation of stability.
Glucose responsiveness of ChREBP is not only de-
pendent on its nuclear localization but also on its ability to
bind the ChoRE present in the promoter of its target genes.
It was previously proposed that Thr-666 dephosphorylation
promotes ChREBP DNA binding and transcriptional acti-
vation (34). However, the fact that mutation of this site
does not result in a constitutively active ChREBP isoform
(9) conﬁrms that the regulation of ChREBP activity in re-
sponse to glucose is complex and may involve multiple
posttranslational modiﬁcations (31) and/or intramolecular
regulations (36,37) like it is the case for other transcription
factors such as FoxO1 whose regulation involves phosphor-
ylation, acetylation, ubiquitination, and/or O-GlcNAcylation
(10). In the current study, we show that ChREBP
OG
increases its recruitment to the L-PK ChoRE under OGT
overexpression conditions as well as its transcriptional
activity toward the L-PK gene in HepG2 cells. When
ChREBP
OG occurred in the context of an active glucose
ﬂux, a potentiating effect on L-PK and lipogenic gene ex-
pression was observed. While ACC, FAS, and SCD1 genes
were described as synergistically regulated by ChREBP and
SREBP-1c (29), we report here that the stimulatory effect of
OGT on lipogenic genes is highly dependent on ChREBP
activity (Fig. 5). In addition, the fact that SREBP-1c O-
GlcNAcylation was not modiﬁed by OGT overexpression
strongly argues for a ChREBP-dependent effect.
Lastly, our results suggest that O-GlcNAcylation may
contribute to increased ChREBP content under hypergly-
cemic conditions (i.e., in the livers of obese mice) and may
lead to excessive hepatic TG deposition. Accumulation of
TG within hepatocytes is the hallmark of nonalcoholic
fatty liver disease, an increasingly common health concern
that encompasses a spectrum of hepatic pathology, rang-
ing from simple steatosis, to steatohepatitis, ﬁbrosis, and
cirrhosis (38). Understanding the molecular steps involved
in TG accumulation in the liver is important, as it may
provide potential therapeutic targets for the treatment and
prevention of nonalcoholic fatty liver disease. Our results
suggest that O-GlcNAcylation may represent an important
modulator of ChREBP activity and could contribute, by
stabilizing and stimulating ChREBP transcriptional activ-
ity, to the phenotype of hepatic steatosis in obese mice
(Fig. 7). Accordingly, modulation of ChREBP
OG in the liver
of OGT mice led to the development of hepatic steatosis,
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ChREBP content/O-GlcNAcylation markedly reduced TG
concentrations in the livers of db/db mice and improved
their lipidic phenotype. It should be noted that the effects we
observed on whole glucose homeostasis and insulin sensi-
tivity upon OGT and/or OGA modulation were also linked
to the modiﬁcation of CRTC2 O-GlcNAcylation and/or of
protein(s) of the insulin signaling pathway, as previously
reported (11,24). Nevertheless, our results emphasize the
importance of ChREBP in the control of hepatic fatty acid
synthesis and reveal that O-GlcNAcylation represents a
novel regulation of ChREBP protein content and activity in
the liver under both physiological and pathophysiological
conditions.
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